Also, BTK inhibition impaired IL-1β processing and release in human primary macrophages from healthy donors, ibrutinib-treated cancer patients, and patients with Muckle–Wells syndrome—an autoinflammatory disease characterized by excessive production of IL-1β [18]. This evidence concerns the gene IL1B and cancer.